Sugi Predict

Sugi Predict / Compounds / SCHEMBL3942944

SCHEMBL3942944

SCHEMBL3942944

CC(C)(C#N)c1cc(C(=O)O)ccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4C Q9H3R0 5/20 0.47
▸ KDM4E B2RXH2 3/20 0.47
▸ KDM6B O15054 3/20 0.47
▸ KDM5C P41229 3/20 0.47
▸ KDM2A Q9Y2K7 3/20 0.47
▸ KDM3A Q9Y4C1 3/20 0.47
▸ KDM4A O75164 2/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ KDM5A P29375 2/20 0.47
▸ KDM5B Q9UGL1 2/20 0.47
▸ TET3 O43151 1/20 0.47
▸ BBOX1 O75936 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ ASPH Q12797 1/20 0.47
▸ KDM4D Q6B0I6 1/20 0.47
▸ TET2 Q6N021 1/20 0.47
▸ ALKBH5 Q6P6C2 1/20 0.47
▸ KDM7A Q6ZMT4 1/20 0.47
▸ KDM8 Q8N371 1/20 0.47
▸ TET1 Q8NFU7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31032276 1.00 KDM4C (0.47) KDM4CKDM4EKDM6BKDM5CKDM2A
SCHEMBL20008477 0.86 MYC (0.46) KDM5CKDM5BLMNASMN1; SMN2RAF1
SCHEMBL25701324 0.86 RAF1 (0.41) LMNASMN1; SMN2RAF1BRAFNPC1
SCHEMBL1759647 0.81 LMNA (0.62) KDM4CKDM4EKDM6BKDM5CKDM2A
SCHEMBL25225199 0.80 JMJD6 (0.48) ALDH1A1RAF1BRAFJMJD6
SCHEMBL29537110 0.80 JMJD6 (0.48) ALDH1A1RAF1BRAFJMJD6
SCHEMBL16094544 0.80 KDM4C (0.53) KDM4CKDM4EKDM6BKDM5CKDM2A
SCHEMBL16095006 0.80 KDM4C (0.53) KDM4CKDM4EKDM6BKDM5CKDM2A
SCHEMBL30069005 0.80 KDM4C (0.53) KDM4CKDM4EKDM6BKDM5CKDM2A
SCHEMBL30893039 0.78 KDM4C (0.52) KDM4CKDM4EKDM6BKDM5CKDM2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509446-B2 FYN and VEGFR2 kinase inhibitors ROTTAPHARM BIOTECH S.R.L. (IT) 2025-12-30 — — US disclosed
US-20250017914-A1 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES BLACK DIAMOND THERAPEUTICS, INC. 2025-01-16 — — US disclosed
CN-115279747-B FYN and VEGFR2 kinase inhibitors 罗达制药生物技术有限责任公司 2024-11-05 — — CN disclosed
US-20240317752-A1 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES BLACK DIAMOND THERAPEUTICS, INC. (US) 2024-09-26 — — US disclosed
EP-4399210-A1 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES Black Diamond Therapeutics, Inc. (US) 2024-07-17 — — EP disclosed
CN-118159537-A 6-Aza-quinoline derivatives and related uses 黑钻治疗公司 2024-06-07 — — CN disclosed
EP-4073057-B1 NEW FYN AND VEGFR2 KINASE INHIBITORS Rottapharm Biotech Srl (IT) 2023-11-29 — — EP disclosed
EP-4073057-B1 NEW FYN AND VEGFR2 KINASE INHIBITORS Rottapharm Biotech Srl (IT) 2023-11-29 — — EP disclosed
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 — — US disclosed
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 — — US disclosed
US-20080306096-A1 Quinazoline Derivatives, Process for Their Preparation and Their Use as Anti-Cancer Agents ASTRAZENECA AB (SE) 2008-12-11 — — US disclosed
US-20080275022-A1 Substituted Quinazolones as Anti-Cancer Agents ASTRAZENECA AB (SE) 2008-11-06 — — US disclosed
EP-1966159-A2 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2008-09-10 — — EP disclosed
US-20080207616-A1 Quinoxalines as B Baf Inhhibitors ASTRAZENECA AB (SE) 2008-08-28 — — US disclosed
US-20080146570-A1 Chemical Compounds ASTRAZENECA AB (SE) 2008-06-19 — — US disclosed
EP-1924573-A1 B-RAF INHIBITORS AstraZeneca AB (SE) 2008-05-28 — — EP disclosed
EP-1831198-A1 PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS AstraZeneca AB (SE) 2007-09-12 — — EP disclosed
WO-2007071963-A2 QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS ASTRAZENECA AB (SE) 2007-06-28 — — WO disclosed
WO-2006079791-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2006-08-03 — — WO disclosed
WO-2006067446-A1 PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS ASTRAZENECA AB (SE) 2006-06-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ERBB2, ERBB3, ERBB4 KDM4C 1245/4885KDM4E 1096/4885KDM6B 817/4885
US-12509446-B2 FYN and VEGFR2 kinase inhibitors FYN, LCK, LYN KDM4C 895/4885KDM4E 792/4885KDM6B 975/4885
US-20080306096-A1 Quinazoline Derivatives, Process for Their Preparation and Their Use as Anti-Cancer Agents BRAF, RAF1, NRAS KDM4C 2682/4885KDM4E 1992/4885KDM6B 2571/4885
US-20240317752-A1 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES TYMP, DPYD, PNP KDM4C 3098/4885KDM4E 3183/4885KDM6B 1492/4885
US-20080275022-A1 Substituted Quinazolones as Anti-Cancer Agents BRAF, NRAS, RAF1 KDM4C 2920/4885KDM4E 2260/4885KDM6B 2181/4885
US-20250017914-A1 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES TOP2A, TOP2B, UGT2B7 KDM4C 270/4885KDM4E 680/4885KDM6B 128/4885
US-20080146570-A1 Chemical Compounds BRAF, RAF1, NRAS KDM4C 3528/4885KDM4E 2971/4885KDM6B 2600/4885
US-20080207616-A1 Quinoxalines as B Baf Inhhibitors BRAF, NRAS, ARAF KDM4C 2092/4885KDM4E 1542/4885KDM6B 1077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.